Novel withanolides target medullary thyroid cancer through inhibition of both RET phosphorylation and the mammalian target of rapamycin pathway

Surgery (United States)

Volumn 152, Issue 6, 2012, Pages 1238-1247

  Samadi, Abbas K ^a   Bazzill, Joseph ^a   Zhang, Xuan ^a   Gallagher, Rob ^b   Zhang, Hauping ^b   Gollapudi, Rao ^b   Kindscher, Kelly ^b   Timmermann, Barbara ^b   Cohen, Mark S ^c  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABOZANTINIB; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN RET; TANESPIMYCIN; UNCLASSIFIED DRUG; VANDETANIB; WITHALONGOLIDE A; WITHALONGOLIDE A 4,19,26 TRIACETATE; WITHALONGOLIDE B 4 ACETATE; WITHALONGOLIDE B 4,19 DIACETATE; WITHALONGOLIDE D; WITHANOLIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THYROID MEDULLARY CARCINOMA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-RET; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TOR SERINE-THREONINE KINASES; TUMOR STEM CELL ASSAY; WITHANOLIDES;

EID: 84869425597     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2012.08.031     Document Type: Article

References (24)

1. G.C. Chong, O.H. Beahrs, G.W. Sizemore, and L.H. Woolner Medullary carcinoma of the thyroid gland Cancer 35 1975 695 704
2. M.S. Cohen, and J.F. Moley Surgical treatment of medullary thyroid carcinoma J Intern Med 253 2003 616 626
3. E.M. Sanders Jr., V.A. LiVolsi, J. Brierley, J. Shin, and G.W. Randolph An evidence-based review of poorly differentiated thyroid cancer World J Surg 31 2007 934 945
4. M. Santoro, and F. Carlomagno Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer Nat Clin Pract Endocrinol Metab 2 2006 42 52
5. L.M. Mulligan, J.B. Kwok, C.S. Healey, M.J. Elsdon, and C. Eng Germ-line mutations of the RET protooncogene in multiple endocrine neoplasia type 2A Nature 363 1993 458 460
6. M. Santoro, and A. Fusco New drugs in thyroid cancer Arch Bras Endocrinol Metabol 51 2007 857 861
7. M. Schlumberger, F. Carlomagno, E. Baudin, J.M. Bidart, and M. Santoro New therapeutic approaches to treat medullary thyroid carcinoma Nat Clin Pract Endocrinol Metab 4 2008 22 32
8. S.I. Sherman Targeted therapy of thyroid cancer Biochem Pharmacol 80 2010 592 601
9. Y. Yokota, P. Bargagna-Mohan, P.P. Ravindranath, K.B. Kim, and R. Mohan Development of withaferin A analogs as probes of angiogenesis Bioorg Med Chem Lett 16 2006 2603 2607
10. L.C. Mishra, B.B. Singh, and S. Dagenais Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review Altern Med Rev 5 2000 334 346
11. L. Misra, P. Mishra, A. Pandey, R.S. Sangwan, N.S. Sangwan, and R. Tuli Withanolides from Withania somnifera roots Phytochemistry 69 2008 1000 1004
12. Q.P. He, L. Ma, J.Y. Luo, F.Y. He, L.G. Lou, and L.H. Hu Cytotoxic withanolides from Physalis angulata L Chem Biodivers 4 2007 443 449
13. A. Grover, A. Shandilya, A. Punetha, V.S. Bisaria, and D. Sundar Inhibition of the NEMO/IKKbeta association complex formation, a novel mechanism associated with the NF-kappaB activation suppression by Withania somnifera's key metabolite withaferin A BMC Genomics 11 Suppl 4 2010 S25
14. A.K. Samadi, R. Mukerji, A. Shah, B.T. Timmermann, and M.S. Cohen A novel RET inhibitor with potent efficacy against medullary thyroid cancer in vivo Surgery 148 2010 1228 1236
15. S. Koduru, R. Kumar, and S. Srinivasan Notch 1 Inhibition by Withaferin-A: A Therapeutic Target against Colon Carcinogenesis Mol Cancer Ther 9 2010 202 210
16. Sagar S. NCT00704730. An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer. 2010. www.clinicaltrials.gov.
17. G.M. Cragg, P.G. Grothaus, and D.J. Newman Impact of natural products on developing new anti-cancer agents Chem Rev 109 2009 3012 3043
18. S.P. Gunasekera, A.D. Kinghorn, G.A. Cordell, and N.R. Farnsworth Plant anticancer agents. XIX Constituents of Aquilaria malaccensis J Nat Prod 44 1981 569 572
19. A.K. Samadi, X. Tong, R. Mukerji, H. Zhang, B.N. Timmermann, and M.S. Cohen Withaferin A, a cytotoxic steroid from Vassobia breviflora, induces apoptosis in human head and neck squamous cell carcinoma J Nat Prod 73 2010 1476 1481
20. A. Samadi, P. Loo, R. Mukerji, B.N. Timmermann, and M.S. Cohen A novel HSP90 modulator with selective activity against thyroid cancers in vitro Surgery 146 2009 1196 1207
21. Stan SD HE, Warin R, Singh SV. Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. Cancer Res 2008;68:7661-9.
22. C. Segouffin-Cariou, and M. Billaud Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway The Journal of Biological Chemistry 275 2000 3568 3576
23. M.A. Kouvaraki, C. Liakou, A. Paraschi, K. Dimas, E. Patsouris, S. Tseleni-Balafouta, G.Z. Rassidakis, and D. Moraitis Activation of mTOR signaling in medullary and aggressive papillary thyroid carcinomas Surgery 150 2011 1258 1265
24. Gota V. A phase I safety and pharmacokinetics study of Withaferin-A in patients with advanced stage high grade osteosarcoma. 4th International Conference on Drug Discovery and Therapy. Feb 2012. Abstract published online http://icddt.com/abstracts/SL/SL-01-29-2012-083-Vikram%20Gota.htm.